Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02397668 · ClinicalTrials.gov registry record · NA

CorMatrix Cor TRICUSPID ECM Valve Replacement Study

A NA study of Tricuspid Valve Disease, sponsored by Corvivo Cardiovascular.

Recruiting
Registry status
NA
Development phase
78
Enrollment target
4
Study locations

NCT02397668 is a NA study of Tricuspid Valve Disease that is actively recruiting participants, run by Corvivo Cardiovascular. The registered enrollment target is 78 participants, below the 320-participant average among 6 other Tricuspid Valve Disease trials with a reported enrollment target (76% lower). The trial reports 4 study locations across 4 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02397668, a NA study of Tricuspid Valve Disease, is actively recruiting participants, sponsored by Corvivo Cardiovascular.

RECRUITING
Registry status
NA
Development phase
78 participants
Enrollment target
4
Study locations

Study Summary

The Pivotal Study of the Cor TRICUSPID ECM Valve (or Cor PEDIATRIC Tricuspid ECM Valve). This study follows the EFS and is now to determine the safety and efficacy of the Cormatrix Cor TRICUSPID Valve for any patients requiring surgical replacement of the tricuspid valve.

Conditions Studied

Interventions

  • DEVICE CorMatrix Cor TRICUSPID ECM Valve

Study Locations (4)

Alabama

  • Springhill Memorial Hospital - Mobile

Indiana

  • St Francis Hospital - Indianapolis

Maryland

  • Medstar - Baltimore

Ohio

  • Cincinnati Children's Hospital - Cincinnati

Trial Details

FieldValue
Enrollment Target 78 participants
Start Date 2022-08-01
Est. Completion 2026-12-15
Phase NA

Sponsor

Corvivo Cardiovascular

2 total trials

What the Registry Record Tells You About NCT02397668

The ClinicalTrials.gov registry entry for NCT02397668 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 78 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 320-participant average among 6 other Tricuspid Valve Disease trials with a reported enrollment target (76% lower). The listed sponsor is Corvivo Cardiovascular, which has 2 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Tricuspid Valve Disease appearing as the primary indexed condition, and to 1 intervention - of which CorMatrix Cor TRICUSPID ECM Valve is the first listed.

NCT02397668 reports 4 study locations spanning 4 distinct geographic areas - top geographies include Alabama, Indiana, Maryland.

Frequently Asked Questions

What is clinical trial NCT02397668 about?

NCT02397668 is a clinical study titled "CorMatrix Cor TRICUSPID ECM Valve Replacement Study". The Pivotal Study of the Cor TRICUSPID ECM Valve (or Cor PEDIATRIC Tricuspid ECM Valve). This study follows the EFS and is now to determine the safety and efficacy of the Cormatrix Cor TRICUSPID Valve for any patients requiring surgical replacement of the tricuspid valve.

What is the current status of trial NCT02397668?

This trial is currently recruiting. It is a NA study. The enrollment target is 78 participants. The study started on 2022-08-01. Estimated completion is 2026-12-15.

What conditions does trial NCT02397668 study?

This clinical trial studies the following conditions: Tricuspid Valve Disease.

What interventions are being tested in trial NCT02397668?

The interventions under investigation include: CorMatrix Cor TRICUSPID ECM Valve (DEVICE).

Who is sponsoring clinical trial NCT02397668?

This trial is sponsored by Corvivo Cardiovascular, which has 2 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02397668 being conducted?

This trial has 4 study locations across Alabama, Indiana, Maryland, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Tricuspid Valve Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.